Man Group plc Purchases New Position in Boston Scientific Corporation $BSX

Man Group plc purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,225,164 shares of the medical equipment provider’s stock, valued at approximately $137,650,000.

Several other hedge funds have also bought and sold shares of the stock. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the fourth quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the first quarter valued at $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.7%

BSX stock opened at $49.86 on Wednesday. The company has a market cap of $72.26 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.07 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a 50-day moving average of $46.44 and a two-hundred day moving average of $57.14.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BSX shares. Bank of America decreased their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. Finally, Robert W. Baird set a $56.00 price objective on Boston Scientific in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.